Mendus AB (publ) (IMMU.ST)
SEK 4.94
(-0.2%)
SEK 4.94
(-0.2%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -96.29 Million SEK | -365.19% |
| 2022 | 36.31 Million SEK | 130.68% |
| 2021 | -118.33 Million SEK | 10.75% |
| 2020 | -132.59 Million SEK | 55.2% |
| 2019 | -295.96 Million SEK | 33.18% |
| 2018 | -442.94 Million SEK | -247.5% |
| 2017 | -127.46 Million SEK | -24.91% |
| 2016 | -102.04 Million SEK | 13.91% |
| 2015 | -118.53 Million SEK | -277.22% |
| 2014 | -31.42 Million SEK | 70.54% |
| 2013 | -106.67 Million SEK | -330.89% |
| 2012 | -24.75 Million SEK | -405.19% |
| 2011 | -4.9 Million SEK | -41.34% |
| 2010 | -3.46 Million SEK | 36.59% |
| 2009 | -5.46 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -63.12 Million SEK | 34.45% |
| 2024 Q2 | -106.39 Million SEK | -68.54% |
| 2023 Q3 | -117.93 Million SEK | -258.75% |
| 2023 FY | -96.29 Million SEK | -365.19% |
| 2023 Q1 | 43.83 Million SEK | 20.71% |
| 2023 Q4 | -96.29 Million SEK | 18.35% |
| 2023 Q2 | 74.28 Million SEK | 69.48% |
| 2022 Q2 | -58.67 Million SEK | 39.57% |
| 2022 Q3 | -28.91 Million SEK | 50.72% |
| 2022 Q4 | 36.31 Million SEK | 225.57% |
| 2022 FY | 36.31 Million SEK | 130.68% |
| 2022 Q1 | -97.09 Million SEK | 17.95% |
| 2021 Q4 | -118.33 Million SEK | 34.61% |
| 2021 Q1 | -117.97 Million SEK | 11.03% |
| 2021 FY | -118.33 Million SEK | 10.75% |
| 2021 Q2 | -210.95 Million SEK | -78.82% |
| 2021 Q3 | -180.96 Million SEK | 14.21% |
| 2020 Q2 | -231.32 Million SEK | 11.9% |
| 2020 Q1 | -262.56 Million SEK | 11.28% |
| 2020 FY | -132.59 Million SEK | 55.2% |
| 2020 Q3 | -196.75 Million SEK | 14.95% |
| 2020 Q4 | -132.59 Million SEK | 32.61% |
| 2019 Q4 | -295.96 Million SEK | 11.19% |
| 2019 FY | -295.96 Million SEK | 33.18% |
| 2019 Q2 | -362.55 Million SEK | 7.63% |
| 2019 Q3 | -333.23 Million SEK | 8.09% |
| 2019 Q1 | -392.5 Million SEK | 11.39% |
| 2018 Q3 | -132.42 Million SEK | 11.2% |
| 2018 Q2 | -149.12 Million SEK | 10.82% |
| 2018 Q1 | -167.21 Million SEK | -31.18% |
| 2018 FY | -442.94 Million SEK | -247.5% |
| 2018 Q4 | -442.94 Million SEK | -234.49% |
| 2017 Q4 | -127.46 Million SEK | -198.27% |
| 2017 Q3 | -42.73 Million SEK | 29.19% |
| 2017 Q2 | -60.35 Million SEK | 27.7% |
| 2017 Q1 | -83.47 Million SEK | 18.2% |
| 2017 FY | -127.46 Million SEK | -24.91% |
| 2016 Q1 | -32.65 Million SEK | 23.58% |
| 2016 Q3 | -118.65 Million SEK | -0.1% |
| 2016 Q4 | -102.04 Million SEK | 14.0% |
| 2016 Q2 | -118.53 Million SEK | -263.01% |
| 2016 FY | -102.04 Million SEK | 13.91% |
| 2015 FY | -118.53 Million SEK | -277.22% |
| 2015 Q4 | -42.72 Million SEK | -64.25% |
| 2015 Q1 | -39.92 Million SEK | 34.83% |
| 2015 Q3 | -26.01 Million SEK | 17.21% |
| 2015 Q2 | -31.42 Million SEK | 21.29% |
| 2014 Q4 | -61.26 Million SEK | 36.79% |
| 2014 FY | -31.42 Million SEK | 70.54% |
| 2014 Q3 | -96.92 Million SEK | 9.14% |
| 2014 Q2 | -106.67 Million SEK | -562.09% |
| 2014 Q1 | -16.11 Million SEK | 16.72% |
| 2013 Q3 | 25.6 Million SEK | 203.43% |
| 2013 Q4 | -19.34 Million SEK | -175.55% |
| 2013 Q2 | -24.75 Million SEK | 0.0% |
| 2013 FY | -106.67 Million SEK | -330.89% |
| 2012 Q3 | -2.42 Million SEK | 50.55% |
| 2012 FY | -24.75 Million SEK | -405.19% |
| 2012 Q4 | -2.42 Million SEK | 0.0% |
| 2012 Q1 | -5.75 Million SEK | 0.0% |
| 2012 Q2 | -4.9 Million SEK | 14.78% |
| 2011 FY | -4.9 Million SEK | -41.34% |
| 2010 FY | -3.46 Million SEK | 36.59% |
| 2009 FY | -5.46 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alzinova AB (publ) | -21.22 Million SEK | -353.661% |
| Amniotics AB (publ) | -5.63 Million SEK | -1609.766% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -4355.993% |
| BioArctic AB (publ) | -606.58 Million SEK | 84.125% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 1883.222% |
| Saniona AB (publ) | 40.44 Million SEK | 338.075% |
| Simris Alg AB (publ) | 85.07 Million SEK | 213.187% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 71.137% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -10332.719% |
| NextCell Pharma AB | -46.79 Million SEK | -105.798% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | -227.72% |
| AcouSort AB (publ) | -23.98 Million SEK | -301.459% |
| Active Biotech AB (publ) | -33.2 Million SEK | -190.042% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | -92.507% |
| Camurus AB (publ) | -1.16 Billion SEK | 91.737% |
| Cantargia AB (publ) | -139.74 Million SEK | 31.094% |
| Genovis AB (publ.) | -43.94 Million SEK | -119.144% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | -14.99% |
| Kancera AB (publ) | -45.69 Million SEK | -110.746% |
| Karolinska Development AB (publ) | -82.2 Million SEK | -17.143% |
| LIDDS AB (publ) | -13.51 Million SEK | -612.655% |
| Lipum AB (publ) | -8.46 Million SEK | -1037.555% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | -201.607% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 280.926% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | -405.215% |
| OncoZenge AB (publ) | -12.62 Million SEK | -662.604% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 157.982% |
| Xintela AB (publ) | -7.8 Million SEK | -1133.116% |
| Ziccum AB (publ) | -2.13 Million SEK | -4406.036% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 30.296% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 25.639% |
| CombiGene AB (publ) | -101.44 Million SEK | 5.073% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | -17.309% |
| Intervacc AB (publ) | -88.16 Million SEK | -9.226% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | -92.843% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 569.498% |
| Corline Biomedical AB | -17.01 Million SEK | -466.036% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | -14.988% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | -144.513% |
| Aptahem AB (publ) | 2.9 Million SEK | 3410.617% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 70.737% |
| Fluicell AB (publ) | -2.76 Million SEK | -3385.125% |
| Biovica International AB (publ) | -58.73 Million SEK | -63.941% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | -112.96% |
| Abliva AB (publ) | -57.24 Million SEK | -68.229% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 50.542% |
| 2cureX AB (publ) | -13.4 Million SEK | -618.451% |
| I-Tech AB | -83.26 Million SEK | -15.652% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 171.484% |
| Cyxone AB (publ) | -16.67 Million SEK | -477.648% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | -72.304% |
| Biosergen AB | -1.88 Million SEK | -5013.861% |
| Nanologica AB (publ) | -9.38 Million SEK | -925.714% |
| SynAct Pharma AB | -61.75 Million SEK | -55.922% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | -349.657% |
| BioInvent International AB (publ) | -236.3 Million SEK | 59.25% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -627.891% |
| Oncopeptides AB (publ) | -66.92 Million SEK | -43.894% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -1758.627% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | -363.108% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -3140.04% |